Comparing the effects of milrinone and olprinone in patients with congestive heart failure

In this report, we retrospectively compared the clinical benefits of two PDE3 inhibitors, milrinone and olprinone, to determine which better controls the progression of CHF. A total of 288 hospitalized patients who received PDE3 inhibitors [(milrinone;n = 77 and olprinone;n = 211, respectively)] for CHF were retrospectively enrolled. The primary endpoint was defined as having a major adverse cardiovascular and cerebrovascular event (MACCE) or cardiac death by day 60. Kaplan–Meier curves and multivariate Cox proportional models were used to compare the outcomes f or patients treated with milrinone and olprinone. We found no significant differences in the baseline characteristics between the two groups. In patients treated with milrinone, a greater incidence of a MACCE or cardiac death was observed (log rank;P = 0.005 andP = 0.01, respectively). Milrinone-treated patients with ischemic heart disease and chronic kidney disease (CKD) at stage ≥ 4 presented with greater incidence of MACCE (log rank;P <  0.001 andP = 0.006, respectively). Similarly, these patients were significantly more likely to succumb to cardiac death (log rank;P <  0.001 andP = 0.02). Multivariate Cox proportional hazard models demonstrated that milrinone treatment was an independent predictor of MACCE [hazard ratio (HR) 3.17; 95% CI 1.64–6.10] and cardiac death (HR 2.64; 95% CI 1.42–4.91). Oral administration of a β-blocker at discharge occurred more often in...
Source: Heart and Vessels - Category: Cardiology Source Type: research